Back to School: How biopharma can reboot drug development. Access exclusive analysis here
GNTA began selling Genasense oblimersen outside the U.S. on a named-patient basis, without restriction with regard to disease
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury